The protocol for a phase 2A, multi centre, double-blind, randomized, placebo-controlled, parallel-group study to assess the effect of 12 weeks treatment with oral PXS-4728A on microglia activation, as measured by positron emission tomography, in participants with isolated rapid eye movement sleep behaviour disorder
6 affiliations
- 1Nuffield Department of Clinical Neurosciences and Oxford Parkinson’s Disease Centre, University of Oxford
- 2Wolfson Brain Imaging Centre, University of Cambridge
- 3Faculty of Medicine, Health and Human Sciences, Macquarie University
- 4Austin Health, University of Melbourne
- 5Olivia Newton-John Cancer Research Institute, La Trobe University
- 6Syntara Limited
Abstract
Introduction: Isolated REM-sleep behaviour disorder (iRBD) is a well-described prodromal feature of synuclein diseases, including Parkinson’s disease (PD), dementia with Lewy bodies and, less frequently, multiple system atrophy. Neuroinflammation has been reported in iRBD and is potentially a major contributor to synuclein accumulation and propagation. Positron emission tomography (PET) imaging of the translocator protein (TSPO) overexpressed by activated microglia has been used to demonstrate neuroinflammation in both iRBD and manifest PD. Although immune-modulating therapies have not shown direct benefit in PD, there are to date no reported trials in prodromal disease. This paper describes the protocol for the first immune-modulating drug trial in iRBD, which could provide evidence for an early neuroprotective intervention strategy in prodromal PD.
Methods and analysis: This is a phase IIa, randomised, double-blind, placebo-controlled, parallel-group trial of the small molecule PXS-4728A in iRBD. Forty participants with definitive iRBD, one or more features of Parkinsonism, impaired olfaction and/or impaired colour vision will be randomised 3:1 (treatment: placebo) for a 12-week treatment period, followed by a 12-week washout. The primary outcome will assess the effect of PXS-4728A on neuroinflammation, measured by PET using the TSPO radioligand [ ¹¹ C]-PK11195 across nigro-striato-cortical regions in the treatment arm (within-arm) from baseline to week 12. Between-arm differences will be treated as exploratory. Drug safety and tolerability will also be assessed as a primary outcome. Secondary outcomes include further regional and whole-brain analysis of [ ¹¹ C]-PK11195 binding. Exploratory outcomes will assess change in clinical scales of prodromal symptoms (motor and non-motor), biological markers from blood and CSF, and digital biomarkers (actigraphy, motor and cognitive).
Study protocol registration: https://clinicaltrials.gov/study/NCT05904717 ; Identifier, NCT05904717.
Related
- In randomized controlled trials with nutrient supplementation, participants with subjective memory complaints should not be combined with those having a mild cognitive impairment diagnosis
- Comparative outcomes of conventional follitropin delta 15 µg/day versus follitropin alfa 225 IU/day for ovarian stimulation: results from an exploratory post hoc analysis of Spanish participants from the ADAPT-1 randomized controlled trial
- Effects of plyometric training combined with tDCS on lower-limb muscle activation and cardiopulmonary function in male amateur soccer players: a randomized controlled trial
- Effectiveness and safety of a New Standardised TrEatment Protocol based on initial/early therapy with single-pill combinations of blood pressure-lowering drugs for improving blood pressure control (NewSTeP): Rationale, design of a randomized clinical trial and baseline characteristics of the trial participants
- Omitting the Eradication Phase of Treatment of Adults with Melioidosis: A Pilot, Single-Center Randomized Controlled Trial
BibTeX
@article{groenewald2026protocol,
title = {{The protocol for a phase 2A, multi centre, double-blind, randomized, placebo-controlled, parallel-group study to assess the effect of 12 weeks treatment with oral PXS-4728A on microglia activation, as measured by positron emission tomography, in participants with isolated rapid eye movement sleep behaviour disorder}},
author = {Karolien Groenewald and Johannes C. Klein and Tim D. Fryer and Graham Smith and Nicolas Dzamko and Michelle Chua and Andrew M. Scott and Jana Baskar and Dieter Hamprecht and Jacqui Everett and Joanna Leadbetter and Michele T. Hu and Simon J. G. Lewis},
journal = {Frontiers in Neurology},
year = {2026},
month = oct,
doi = {10.3389/fneur.2026.1951452},
url = {https://www.frontiersin.org/articles/10.3389/fneur.2026.1951452/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The protocol for a phase 2A, multi centre, double-blind, randomized, placebo-controlled, parallel-group study to assess the effect of 12 weeks treatment with oral PXS-4728A on microglia activation, as measured by positron emission tomography, in participants with isolated rapid eye movement sleep behaviour disorder
AU - Karolien Groenewald
AU - Johannes C. Klein
AU - Tim D. Fryer
AU - Graham Smith
AU - Nicolas Dzamko
AU - Michelle Chua
AU - Andrew M. Scott
AU - Jana Baskar
AU - Dieter Hamprecht
AU - Jacqui Everett
AU - Joanna Leadbetter
AU - Michele T. Hu
AU - Simon J. G. Lewis
PY - 2026
DA - 2026/10/28
JO - Frontiers in Neurology
DO - 10.3389/fneur.2026.1951452
UR - https://www.frontiersin.org/articles/10.3389/fneur.2026.1951452/full
AB - Introduction: Isolated REM-sleep behaviour disorder (iRBD) is a well-described prodromal feature of synuclein diseases, including Parkinson’s disease (PD), dementia with Lewy bodies and, less frequently, multiple system atrophy. Neuroinflammation has been reported in iRBD and is potentially a major contributor to synuclein accumulation and propagation. Positron emission tomography (PET) imaging of the translocator protein (TSPO) overexpressed by activated microglia has been used to demonstrate neuroinflammation in both iRBD and manifest PD. Although immune-modulating therapies have not shown direct benefit in PD, there are to date no reported trials in prodromal disease. This paper describes the protocol for the first immune-modulating drug trial in iRBD, which could provide evidence for an early neuroprotective intervention strategy in prodromal PD. Methods and analysis: This is a phase IIa, randomised, double-blind, placebo-controlled, parallel-group trial of the small molecule PXS-4728A in iRBD. Forty participants with definitive iRBD, one or more features of Parkinsonism, impaired olfaction and/or impaired colour vision will be randomised 3:1 (treatment: placebo) for a 12-week treatment period, followed by a 12-week washout. The primary outcome will assess the effect of PXS-4728A on neuroinflammation, measured by PET using the TSPO radioligand [ ¹¹ C]-PK11195 across nigro-striato-cortical regions in the treatment arm (within-arm) from baseline to week 12. Between-arm differences will be treated as exploratory. Drug safety and tolerability will also be assessed as a primary outcome. Secondary outcomes include further regional and whole-brain analysis of [ ¹¹ C]-PK11195 binding. Exploratory outcomes will assess change in clinical scales of prodromal symptoms (motor and non-motor), biological markers from blood and CSF, and digital biomarkers (actigraphy, motor and cognitive). Study protocol registration: https://clinicaltrials.gov/study/NCT05904717 ; Identifier, NCT05904717.
SN - 1664-2295
ER -